|Bid||3.7600 x 800|
|Ask||3.8600 x 1800|
|Day's Range||3.6000 - 3.8900|
|52 Week Range||2.4600 - 10.6800|
|Beta (3Y Monthly)||2.34|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The study also demonstrated a dose range which the Company believes will restore normal KLK1 levels in CKD patients. It is noteworthy that the pharmacokinetic (PK) profile in CKD subjects after dosing was similar to the PK profile in healthy volunteers.
DiaMedica Therapeutics Inc. (DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today announced the formation of a Scientific Advisory Board (“SAB”) for chronic kidney disease (“CKD”). The members of the SAB are world-leading experts in CKD and hypertension. The SAB will work closely with DiaMedica’s senior management team to advance the company’s lead product candidate, DM199, in the treatment of chronic kidney disease.
NEW YORK, NY / ACCESSWIRE / May 14, 2019 / DiaMedica Therapeutics, Inc. (NASDAQ: DMAC ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 14, 2019 at 8:00 ...
Phase Ib study of DM199 in Chronic Kidney Disease nearing full enrollmentCompletion of new cGMP manufacturing run of DM199Conference call with management tomorrow, May 14, 2019.
MINNEAPOLIS, May 06, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its first quarter 2019 financial results will be released after market close on.
DiaMedica Therapeutics Inc. (DMAC), a clinical-stage biotechnology company, today announced that Dr Harry Alcorn, its Chief Medical Officer will be presenting “CKD New Therapeutic Development: DM199 for Chronic Kidney Disease” at the Chronic Kidney Disease Drug Development (“CKD3”) summit in Boston on Tuesday May 7, 2019, at 1:30 Eastern Time. CKD3 is a uniquely focused conference that unites key opinion leaders to identify and discuss critical factors in determining the success of current chronic kidney disease (“CKD”) pipelines and evaluate new treatments that have the potential to significantly impact the standard of care for this serious unmet medical need. Leading experts from innovative biotechnology and pharmaceutical companies, academia and key service providers come together at the CKD3 summit to present comprehensive insight into the cutting-edge progress of CKD drug development research.
Dosed first patients in Phase Ib study of DM199 in Chronic Kidney Disease patients under an IND accepted by the FDA in 2018; Plan to initiate Phase II studies in 2H 2019Acute.
MINNEAPOLIS, March 18, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March.
MINNEAPOLIS, March 12, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The.
DiaMedica Therapeutics Inc. (DMAC), a clinical-stage biotechnology company, today announced that it has initiated dosing patients with chronic kidney disease (“CKD”) in a Phase Ib clinical study evaluating DM199. The Phase 1b study, conducted in the US, is a multi-center, open label clinical trial to evaluate the safety, tolerability and pharmacokinetics of three dose levels of DM199 in 32 patients with moderate and severe CKD. “This study will assist in determining dose levels required to restore normal KLK1 protein levels in patients with CKD and provide additional insights about the specific CKD patient populations that may benefit most from DM199 treatment and to guide the design of upcoming Phase II studies,” said Dr. Harry Alcorn, Chief Medical Officer at DiaMedica Therapeutics.
MINNEAPOLIS, Jan. 22, 2019 -- DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announces the publication of a paper titled “Human Tissue Kallikrein In The Treatment Of Acute Ischemic.
NEW YORK , Jan. 16, 2018 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the fourth quarter 2018 performance ...
DiaMedica Therapeutics Inc. (DMAC) (DMA.V), a clinical stage biopharmaceutical company, announced today that it has applied to voluntarily delist its voting common shares from the TSX Venture Exchange. The Company’s common shares are expected to be delisted from the TSX-V at the close of business on January 18, 2019, being approximately 10 days from today's date. DiaMedica’s shares will continue to be listed for trading on The Nasdaq Capital Market (“Nasdaq”) under the trading symbol “DMAC.” The Company believes that the continued listing of its common shares on the Nasdaq will provide its Canadian shareholders with a sufficiently liquid market and further, that the financial and administrative costs associated with maintaining a dual listing are not justified.
DiaMedica Therapeutics Inc. (“DiaMedica”) (DMAC) (DMA.V) announced today that the U.S. Food and Drug Administration ("FDA") has accepted DiaMedica’s Investigational New Drug application ("IND") for the initiation of a Phase Ib clinical trial of DM199 in patients with moderate or severe Chronic Kidney Disease (“CKD”) caused by Type I or Type II diabetes. The multi-site clinical study will enroll 32 subjects to evaluate DM199 safety, tolerability and drug levels (pharmacokinetics) in this specific population. The results from this Phase Ib study will assist DiaMedica in the design of upcoming Phase II studies in patients suffering from rare diseases and CKD.